



# Test Definition: GP210

GP210 Antibody, IgG, Serum

## Overview

### Useful For

Evaluating the risk of primary biliary cholangitis in anti-mitochondrial antibody (AMA)-negative patients by identification of gp210 antibodies

Estimating risk in AMA-positive patients with incomplete feature of disease

### Testing Algorithm

For information see [First-Line Screening for Autoimmune Liver Disease Algorithm](#).

### Special Instructions

- [First-Line Screening for Autoimmune Liver Disease Algorithm](#)

### Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Additional Testing Requirements

This is a first line test when primary biliary cholangitis is strongly suspected. This test should be ordered in conjunction with testing for mitochondrial antibodies (M2) (AMA / Mitochondrial Antibodies [M2], Serum), SP100 antibodies (SP100 / SP100 Antibody, IgG, Serum), and antinuclear antibodies (NAIFA / Antinuclear Antibodies, HEp-2 Substrate, IgG, Serum).

### Specimen Required

**Supplies:** Sarstedt Aliquot Tube, 5 mL (T914)

**Collection Container/Tube:**

**Preferred:** Serum gel

**Acceptable:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 0.5 mL Serum

**Collection Instructions:** Centrifuge and aliquot serum into a plastic vial.

### Forms

If not ordering electronically, complete, print, and send a [Gastroenterology and Hepatology Test Request \(T728\)](#) with the specimen.

## Specimen Minimum Volume

Serum: 0.4 mL

## Reject Due To

Gross hemolysis	OK
Gross lipemia	OK
Gross icterus	OK
Heat-treated specimens	Reject

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	21 days	
	Frozen	21 days	

## Clinical & Interpretive

### Clinical Information

Primary biliary cholangitis (PBC) is a chronic and progressive autoimmune liver disease characterized by the destruction of small intrahepatic bile ducts and a variable clinical course, which may include fatigue and pruritus. Untreated patients with PBC have a high risk of liver cirrhosis and related complications such as liver failure and death.(1,2) The serological hallmark of PBC is the presence of anti-mitochondrial antibody (AMA) characterized by cytoplasmic reticular/AMA (anti-cell 21 [AC-21] based on the International Consensus on Antinuclear Antibody Patterns [ICAP] nomenclature) staining pattern on HEp-2 substrate by indirect immunofluorescence assay (IFA).(3) In addition, autoantibodies associated with the HEp-2 IFA nuclear patterns have been reported in a subset of patients with PBC who are seronegative for AMA or may be positive for AMA but have uncertain clinical or phenotypic attributes.(2,4,5) The HEp-2 IFA nuclear patterns in PBC include multiple nuclear dots (MND or AC-6) and punctate nuclear envelope (AC-12), which are associated with anti-Sp100 and anti-gp210 antibodies, respectively.(3) The diagnosis of PBC can be established if two out of the three following criteria are met: sustained elevated levels of alkaline phosphatase (ALP), evidence AMA or specific antinuclear antibody (ANA) (anti-Sp100 and anti-gp210 antibodies) and diagnostic liver histology.(2) Based on these criteria, a biopsy can be avoided in case of high ALP levels and detection of PBC-specific autoantibodies.(1,2) Therefore, reliable and accurate serologic determination of PBC-specific autoantibodies play a critical role in disease evaluation.

Of the PBC-specific antibodies, AMA is the most common, with the M2-type AMA (AMA-M2) the dominant target of the 9 subunits of the mitochondrial antigenic complex.( 2) In addition to AMA, anti-gp210 IgG antibodies can be found in PBC patients who are seropositive or seronegative for AMA. In the context of AMA-negative PBC, the presence of anti-gp210 IgG antibody associated with clinical and laboratory features of disease is of diagnostic significance.( 2) The

likelihood of PBC is also increased in at-risk or asymptomatic patients who test positive for both AMA and anti-gp210 IgG antibodies.(5) In addition to the diagnostic relevance of anti-gp210 IgG antibody, a few studies have suggested a role for their use in the risk stratification and prognosis in PBC, however, the significance of these remain contentious. In one study, the presence of anti-gp210 antibodies was reported to pose a significant risk for hepatic failure type progression, more severe interface hepatitis and lobular inflammation compared to those with centromere antibodies who had relatively higher ductular reaction.(6)

Anti-gp210 antibodies can be detected and quantified using solid-phase immunoassays (SPA), such as enzyme-linked immunosorbent assay line blot immunoassay, and dot immunoassay.(4-8) Although anti-gp210 antibodies have been reported to be associated with a positive punctate nuclear envelope (AC-12) HEp-2 IFA pattern, a recent investigation by the Antibody Immunology Laboratory at Mayo Clinic showed no positive correlation between anti-gp210 IgG and the punctate nuclear envelope pattern. These observations suggest testing for anti-gp210 IgG antibodies in the absence of a positive punctate nuclear envelope pattern when clinical suspicion for PBC is high. While HEp-2 IFA is not reliable for the detection of anti-gp210 IgG antibodies, it offers the possibility to identify patients at-risk for PBC who may present with coexisting systemic autoimmune rheumatic diseases (systemic lupus erythematosus, systemic sclerosis, and Sjogren syndrome) or autoimmune liver disease (autoimmune hepatitis) through additional pattern recognition. The use of SPA for ANA testing does not provide these additional diagnostic insights.

### Reference Values

Negative: < or =20.0 Units

Equivocal: 20.1-24.9 Units

Positive: > or =25.0 Units

### Interpretation

A positive result for anti-gp210 antibodies in the setting of chronic cholestasis after exclusion of other causes of liver disease is highly suggestive of primary biliary cholangitis.

### Cautions

The presence of primary biliary cholangitis (PBC)-specific autoantibodies, including anti-gp210, should not be relied upon exclusively to make a diagnosis of PBC or predict disease outcome.

A negative result for anti-gp210 antibodies does not exclude a diagnosis of PBC.

Results of this assay should be used in conjunction with clinical findings and other serological tests.

### Clinical Reference

1. Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. *Expert Rev Clin Immunol*. 2014;10(12):1667-1678
2. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance update from the American Association for the Study of Liver Diseases. *Hepatology*. 2019;69(1):394-419
3. International Consensus on ANA Patterns. AC-20 Cytoplasmic fine speckled. ICAP; 2015. Accessed December 24, 2025. Available at [www.anapatterns.org/view\\_pattern.php?pattern=20](http://www.anapatterns.org/view_pattern.php?pattern=20)
4. Zhang Q, Liu Z, Wu S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. *Gastroenterol Res Pract*. 2019;2019:8959103
5. Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. *Hepatology*. 2017;65(1):152-163

6. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. *Hepatology*. 2007;45(1):118-127
7. Jaskowski TD, Nandakumar V, Novis CL, Palmer M, Tebo AE. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis. *Clin Chim Acta*. 2023;540:117219
8. Munoz-Sanchez G, Perez-Isidro A, Ortiz de Landazuri I, et al. Working algorithms and detection methods of autoantibodies in autoimmune liver disease: A nationwide study. *Diagnostics (Basel)*. 2022;12(3):697
9. Favoino E, Grapsi E, Barbuti G, et al. Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity. *Clin Exp Immunol*. 2023;212(1):32-38
10. Wei Q, Jiang Y, Xie J, et al. Investigation and analysis of HEp 2 indirect immunofluorescence titers and patterns in various liver diseases. *Clin Rheumatol*.2020;39(8):2425-2432. doi:10.1007/s10067-020-04950-7

## Performance

### Method Description

This test is intended for the semi-quantitative detection of anti-gp210 antibody of the IgG class in human serum. A purified peptide corresponding to a portion of the gp210 protein is bound to the wells of a polystyrene microwell plate. Pre-diluted controls and diluted patient sera are added to separate wells, allowing any gp210 antibodies present to bind to the immobilized antigen. Unbound sample is washed away, and an enzyme labeled anti-human IgG conjugate is added to each well. A second incubation allows the enzyme labeled anti-human IgG to bind to any patient antibodies, which have become attached to the microwells. After washing away any unbound enzyme labeled anti-human IgG, the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops. The assay can be evaluated spectrophotometrically by measuring and comparing the color intensity that develops in the patient wells with the control in the control wells. (Package insert: QUANTA Lite gp210 ELISA 708995. INOVA Diagnostics; Rev. 5, 04/2019)

### PDF Report

No

### Day(s) Performed

Tuesday

### Report Available

2 to 8 days

### Specimen Retention Time

14 days

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Superior Drive

## Fees & Codes

---

**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

**CPT Code Information**

83516

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
GP210	GP210 Antibody, IgG, S	96560-8

Result ID	Test Result Name	Result LOINC® Value
GP210	GP210 Antibody, IgG, S	96560-8